HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.03.068v1 50/12/1189    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Butera, G. Articles by Frigiola, A. Search for Related Content PubMed Articles by Butera, G. Articles by Frigiola, A.

CLINICAL RESEARCH: CONGENITAL HEART DISEASE

Transcatheter Closure of Perimembranous Ventricular Septal Defects

Early and Long-Term Results

Department of Pediatric Cardiology and GUCH Unit, Policlinico San Donato, Instituto Ricerca e Cura a Carattere Scientifico, San Donato Milanese, Italy.

Manuscript received September 22, 2006; revised manuscript received February 15, 2007, accepted March 21, 2007.

^_* Reprint requests and correspondence: Dr. Gianfranco Butera, Pediatric Cardiology, Policlinico San Donato, IRCCS, Via Morandi, 30-20097 San Donato Milanese (MI), Italy. (Email: gianfra.but{at}lycos.com).

Objectives: We sought to analyze safety, efficacy, and follow-up results of percutaneous closure of perimembranous ventricular septal defects (pmVSD).

Background: Results of pmVSD transcatheter closure have been reported in the literature; however, follow-up data are still limited.

Methods: Between January 1999 and June 2006, 104 patients underwent percutaneous closure of a pmVSD at our institution. An Amplatzer VSD device (muscular or eccentric) (AGA Medical Corp., Golden Valley, Minnesota) was used in all subjects.

Results: The mean age at closure was 14 years (range 0.6 to 63 years). The attempt to place a device was successful in 100 patients (96.2%). The median device size used was 8 mm (range 4 to 16 mm). No deaths occurred. Total occlusion rate was 47% at completion of the procedure, rising to 84% at discharge and 99% during the follow-up. A total of 13 early complications occurred (11.5%), but in all but 2 subjects (1.9%) these were transient. The median follow-up was 38.5 months. The most significant complication was complete atrioventricular block (cAVB), which required pacemaker implantation in 6 subjects (5.7%; 2 in the early phase and 4 during the follow-up). Cox proportional hazards regression analysis showed that the only variable significantly associated with the occurrence of this complication was age at the time of the procedure (p = 0.028; relative risk 0.25). All subjects experiencing this problem were <6 years old.

Conclusions: In the current era and in experienced hands, pmVSD closure can be performed safely and successfully. The major concern is the occurrence of cAVB; therefore, very careful monitoring of rhythm is mandatory during follow-up.

Abbreviations and Acronyms   cAVB = complete atrioventricular block   MVSD-O = muscular ventricular septal defect occluder   pmVSD = perimembranous ventricular septal defect   PMVSD-O = perimembranous ventricular septal defect occluder   TEE = transesophageal echocardiography   TTE = transthoracic echocardiography

This article has been cited by other articles:

				C. Gan, Q. An, K. Lin, H. Tang, R. C. Lui, K. Tao, W. Pan, and Y. Shi Perventricular device closure of ventricular septal defects: six months results in 30 young children. Ann. Thorac. Surg., July 1, 2008; 86(1): 142 - 146. [Abstract] [Full Text] [PDF]

				E. A. Bacha Invited commentary. Ann. Thorac. Surg., July 1, 2008; 86(1): 146 - 146. [Full Text] [PDF]

				A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al. Highlights of the year in JACC 2007. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512. [Full Text] [PDF]